|
EXOC6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.85879999673E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.10710000003722E-07 |
| Normal-vs-Stage2 |
3.015400E-04 |
| Normal-vs-Stage3 |
2.18179999622592E-08 |
| Normal-vs-Stage4 |
1.73219999999308E-06 |
| Stage1-vs-Stage2 |
7.073600E-01 |
| Stage1-vs-Stage3 |
2.898400E-01 |
| Stage1-vs-Stage4 |
2.551400E-01 |
| Stage2-vs-Stage3 |
2.828400E-01 |
| Stage2-vs-Stage4 |
2.643600E-01 |
| Stage3-vs-Stage4 |
7.373600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.94150000520921E-08 |
| Normal-vs-AfricanAmerican |
5.498300E-02 |
| Normal-vs-Asian |
1.66639999577001E-08 |
| Caucasian-vs-AfricanAmerican |
8.855800E-02 |
| Caucasian-vs-Asian |
2.854400E-01 |
| AfricanAmerican-vs-Asian |
6.287600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.17369999947026E-07 |
| Normal-vs-Female |
6.59600000174621E-08 |
| Male-vs-Female |
4.446000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.78499999962057E-07 |
| Normal-vs-Age(41-60Yrs) |
6.45850000147163E-08 |
| Normal-vs-Age(61-80Yrs) |
2.34470000000098E-05 |
| Normal-vs-Age(81-100Yrs) |
3.881500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.187800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.590800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.113000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.029200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.427600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.914600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.807600E-02 |
| Classical-VS-Follicular |
4.141600E-01 |
| Classical-VS-Other |
4.052800E-01 |
| Classical-VS-Normal |
1.88579999949035E-07 |
| Tall-VS-Follicular |
3.506000E-02 |
| Tall-VS-Other |
9.224400E-01 |
| Tall-VS-Normal |
2.21620000018241E-07 |
| Follicular-VS-Other |
3.296800E-01 |
| Follicular-VS-Normal |
3.616400E-04 |
| Other-VS-Normal |
3.321600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.21170000000337E-06 |
| Normal-vs-N1 |
2.06810013558822E-10 |
| N0-vs-N1 |
8.017700E-03 |
|
|
